Cambridge small-molecule therapeutics developer Forma Therapeutics Inc. has partnered with Emerald BioStructures for the structure-based development of potential cancer drug targets.
The partnership uses Bainbridge Island, Wash.-based Emerald BioStructures’ X-ray crystallography in combination with Forma Therapeutic’s Diversity Oriented Synthesis (DOS) chemistry.
No financial terms of the partnership deal were disclosed, but some funding will be used to cover several full-time employees at Emerald, according to a press release today from the two companies.
Emerald BioStructures is a gene-to structure contract research organization that assists biotechnology firms, pharmaceutical companies, government organizations and academic institutions.
Forma announced in March that it was partnering with the Leukemia & Lymphoma Society  to try to develop drug candidates against a promising lymphoma target.